Madrigal Pharmaceuticals (MDGL) Stock Soars on Promising Two-Year Rezdiffra Data for Fatty Liver Cirrhosis

26 February, 2025 | 2 Min Read

tickers: MDGL

tickers affected by this

ticker	polarity	why?
MDGL	negatively	The positive data from the Phase 3 trial of Rezdiffra could lead to increased investor expectations, which might negatively affect the ticker if future trials or regulatory submissions do not meet these high expectations. Additionally, the significant stock surge of 20.30% might create a temporary peak, and any future news or data that doesn’t align with this positive trajectory could result in a sell-off, leading to a negative impact on the stock price.

our strategies and bots using these tickers

None so far…

summary

Madrigal Pharmaceuticals Stock Surges on Positive Two-Year Data for Rezdiffra in Compensated Fatty Liver Cirrhosis

February 26, 2025 – Madrigal Pharmaceuticals, Inc. (MDGL) reported significant two-year data from the open-label compensated MASH cirrhosis (F4c) arm of its Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). The study showed a mean reduction in liver stiffness by 6.7 kPa, with 51% of patients achieving a 25% or greater improvement. Patients in the trial, who had compensated MASH cirrhosis, showed marked reductions in liver stiffness. Starting with a mean baseline of 25 kPa. Following two years of treatment, the results demonstrated a mean 6.7 kPa decrease in liver stiffness, from a 6.1 kPa reduction after the first year. Of the 101 patients analyzed, 51% had a significant decrease in liver stiffness. This response is associated with a reduced progression to end-stage liver disease. Madrigal anticipates using this data to support ongoing trials and regulatory submissions. Concurrently, Madrigal also revealed its fourth-quarter financial results, posting a loss of $2.71 per share, compared to a loss of $5.68 per share a year ago. The company exceeded analysts’ estimates of a $4.16 per share loss. Additionally, sales reached $103.22 million, surpassing the $98.56 million consensus. madrigal Pharmaceuticals Chief Executive Officer Bill Sibold highlighted the company’s achievements in 2024. “We secured FDA approval for Rezdiffra in march. executed a large launch which showed strong results and are poised for continued success. It will be an exciting year,” Sibold said. The revealed promising data significantly lifted Madrigal’s stock. MDGL shares climbed 20.30% to $372.26.